Home › Chronic Inflammatory Demyelinating Polyradiculoneuropathy › Alabama › Birmingham
Chronic Inflammatory Demyelinating Polyradiculoneuropathy clinical trials in Birmingham, AL
4 studies for Chronic Inflammatory Demyelinating Polyradiculoneuropathy are looking for participants at sites in and around Birmingham (within about 30 miles). Open a study to see who can join and how to contact the study team.
A Study to Assess the Efficacy and Safety of Empasiprubart in Adults With CIDP
RecruitingPhase 3
- University of Alabama at Birmingham - 1720 University Blvd, Birmingham
A Study to Assess Efficacy and Safety of Empasiprubart Versus IVIg in Adults With CIDP
RecruitingPhase 3
- University of Alabama, Birmingham
A Study to Test the Efficacy and Safety of Riliprubart Against the Usual Treatment of Intravenous Immunoglobulin (IVIg) in People With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
RecruitingPhase 3
- Alabama Neurology Associates- Site Number : 8400019, Homewood · 3 mi away
A Study to Evaluate the Efficacy and Safety of DNTH103 in Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CAPTIVATE)
RecruitingPhase 3
- Clinical Study Site, Birmingham
Chronic Inflammatory Demyelinating Polyradiculoneuropathy trials in other cities
- New York City, NY7 studies
- Houston, TX6 studies
- Miami, FL6 studies
- Indio, CA5 studies
- Philadelphia, PA5 studies
- Kansas City, KS5 studies
- St. Louis, MO5 studies
- New Haven, CT5 studies
- Washington, DC4 studies
- Tampa, FL4 studies
- Milwaukee, WI4 studies
- Cleveland, OH4 studies
Other studies in Birmingham
- Cancer (all types)31 studies
- Breast Cancer24 studies
- Obesity23 studies
- Ovarian Cancer23 studies
- Non-Small Cell Lung Cancer22 studies
- Acute Myeloid Leukemia21 studies
- Multiple Myeloma18 studies
- Cardiovascular Disease17 studies
- COPD17 studies
- Overweight16 studies
- Cystic Fibrosis16 studies
- Endometrial Cancer16 studies
From ClinicalTrials.gov, data retrieved Oct 1, 2026. Each study sets its own eligibility; the study team decides who can join.